BioSpace News Archive

First Wave BioPharma, Inc. announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the issuance and sale of an aggregate of 6,498,195 shares of its common stock and warrants to purchase up to an aggregate of 6,498,195 shares of common stock at an effective purchase price of $1.385 per share and accompanying warrant in a registered direct offering priced at-the-market under Nasdaq rules.

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the launch of the NuVent™ Eustachian tube dilation balloon, which has been cleared by the U.S. Food and Drug Administration (FDA) for the treatment of chronic, obstructive Eustachian Tube Dysfunction.

Kazia Therapeutics Limited is pleased to announce that a phase II study of Kazia’s investigational new drug, paxalisib, in combination with metformin and a ketogenic diet for the treatment of newly diagnosed and recurrent glioblastoma, has been initiated at Weill Cornell Medicine, with the first patient successfully initiated in the study and a second patient already in screening.

Seelos Therapeutics, Inc. today announced the dosing of the first participants in its registrational Phase II/III trial studying the investigational treatment SLS-005.

Rallybio Corporation today announced that Martin Mackay, Ph.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “ Neuromuscular” at the Cowen 42nd Annual Health Care Conference on Monday, March 7, 2022.

Avinger, Inc., a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease, announced that physicians in the U.S. have successfully completed first cases with its new Lightbox 3 imaging console.

Masimo (NASDAQ: MASI) announced today the FDA clearance of SedLine® brain function monitoring for pediatric patients (1-17 years of age) and the SedLine Pediatric EEG Sensor.

Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the t

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that it has resubmitted the New Drug Application (NDA) for DefenCath to address the Complete Response Letter (CRL) issued by the U.S. Food and Drug Administration (FDA) a year ago.

Caring Cross, a 501(c)(3) announced that Kim Anthony-Gonda, Ph.D., Director of Infectious Diseases at Caring Cross, presented a poster highlighting the organization’s Anti-HIV DuoCAR-T Cell Therapy at the Conference on Retroviruses and Opportunistic Infections (CROI) 2022.